Inpatient Penicillin Allergy Delabeling Study

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 22, 2021

Primary Completion Date

March 30, 2022

Study Completion Date

March 30, 2022

Conditions
Penicillin AllergyPenicillin SensitivityPenicillin ReactionPenicillin Intolerance
Interventions
DRUG

Graded Oral Amoxicillin Challenge

Oral amoxicillin at 45 mg/kg (maximum of 1000 mg) to be divided into two doses: 10 % initial dose and then 90% remaining dose - doses will be separated by 30 minute interval

OTHER

De-labelling in electronic medical record

Patients with No Risk for allergic reaction will be de-labelled for allergy in the electronic medical record.

OTHER

Referral to Allergy Immunology/Retention of Allergy Label

Patients deemed to be High Risk for allergic reaction will be referred to Allergy Immunology as outpatient and allergy label will be retained.

Trial Locations (1)

44106

University Hospitals Rainbow Babies and Children's Hospital, Cleveland

All Listed Sponsors
lead

University Hospitals Cleveland Medical Center

OTHER

NCT05020327 - Inpatient Penicillin Allergy Delabeling Study | Biotech Hunter | Biotech Hunter